Genome-wide gene copy number and expression analysis of primary gastric tumors and gastric cancer cell lines by Junnila, Siina et al.
RESEARCH ARTICLE Open Access
Genome-wide gene copy number and expression
analysis of primary gastric tumors and gastric
cancer cell lines
Siina Junnila1, Arto Kokkola2, Marja-Liisa Karjalainen-Lindsberg3, Pauli Puolakkainen2,4, Outi Monni1*
Abstract
Background: Gastric cancer is one of the most common malignancies worldwide and the second most common
cause of cancer related death. Gene copy number alterations play an important role in the development of gastric
cancer and a change in gene copy number is one of the main mechanisms for a cancer cell to control the
expression of potential oncogenes and tumor suppressor genes.
Methods: To highlight genes of potential biological and clinical relevance in gastric cancer, we carried out a
systematic array-based survey of gene expression and copy number levels in primary gastric tumors and gastric
cancer cell lines and validated the results using an affinity capture based transcript analysis (TRAC assay) and real-
time qRT-PCR.
Results: Integrated microarray analysis revealed altogether 256 genes that were located in recurrent regions of
gains or losses and had at least a 2-fold copy number- associated change in their gene expression. The expression
levels of 13 of these genes, ALPK2, ASAP1, CEACAM5, CYP3A4, ENAH, ERBB2, HHIPL2, LTB4R, MMP9, PERLD1, PNMT,
PTPRA, and OSMR, were validated in a total of 118 gastric samples using either the qRT-PCR or TRAC assay. All of
these 13 genes were differentially expressed between cancerous samples and nonmalignant tissues (p < 0.05) and
the association between copy number and gene expression changes was validated for nine (69.2%) of these genes
(p < 0.05).
Conclusion: In conclusion, integrated gene expression and copy number microarray analysis highlighted genes
that may be critically important for gastric carcinogenesis. TRAC and qRT-PCR analyses validated the microarray
results and therefore the role of these genes as potential biomarkers for gastric cancer.
Background
Due to the lack of early symptoms gastric adenocarci-
noma is characterized by late stage diagnosis and unsa-
tisfactory options for curative treatment [1,2]. Despite
the decline in its incidence in the past few decades, gas-
tric cancer remains the second most common cause of
cancer-related deaths worldwide [3]. Approximately 90%
of all gastric cancers are adenocarcinomas arising from
the epithelium [4]. According to Laurén’s classification
gastric cancers are divided into two main histological
subtypes, intestinal and diffuse [5].
Gastric adenocarcinomas, like many other solid
tumors of epithelial origin, are often complex in terms
of chromosomal integrity [6,7]. Malignant gastric tumors
are known to carry multiple aberrations in their genome
and such chromosomal alterations are crucial for the
activation and inactivation of cancer-related genes
[8-17]. Gene copy number change is one of the main
mechanisms for a cancer cell to control the expression
of genes pivotal to cell survival and cancer progression
[17-22]. These copy number alterations often involve a
large group of genes located close to one another in the
same chromosome. For example; in gastric cancers the
frequently amplified 17q12-q21 region contains genes
such as ERBB2, GRB7, JUP, PERLD1, PNMT, PPP1R1B,
STARD3, and TOP2A [14,17,23]. However, only a min-
ority of these genes are likely to be the true cancer
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driver genes contributing to tumorigenesis, while others
may be amplified simply because of their chromosomal
proximity with the amplification target genes [24,25].
One approach to distinguish such driver genes from the
passenger mutations is to integrate genome-wide copy
number and expression data, which enables the identifi-
cation of genes whose transcriptional activation or
repression is associated with a copy number change in a
cancer cell. Thus, by combining information from the
high resolution gene copy number and expression
microarrays, it is possible not only to define breakpoints
of copy number changes in great detail, but also to
assess the functional significance of these changes and
therefore possibly identify genes that drive cancer onset
and progression.
To highlight genes potential as biomarkers or clinical
targets in gastric cancer, we carried out a systematic
high-resolution array-based survey of copy number and
gene expression levels in gastric cancer tissues and cell
lines. Our previous array-based analysis showed that
copy number gains and losses of hundreds of genes are
associated with a simultaneous increase or decrease in
gene expression [17]. In the present study, we have
increased the resolution of the copy number analysis
over 20-fold to more accurately visualize the break-
points of the copy number alterations. Furthermore, we
have carried out a transcriptional analysis of genes
located in altered chromosomal regions to identify
genes whose deregulation is associated with the malig-
nant phenotype.
Methods
Gastric cancer tissues and cell lines
This research project has been reviewed and approved
by the Ethical Committee of the Department of Medical
Genetics and Surgery and authorized by the Clinical
Review Board of Helsinki University Central Hospital.
Gastric tissue samples were prospectively collected from
patients who underwent gastric surgery or gastroscopy
in the Helsinki University Central Hospital between
1999 and 2007. Informed consent was obtained from
each participating patient. Thirteen fresh frozen primary
gastric cancer tissues and seven gastric cancer cell lines
were chosen for microarray analysis (Table 1). The tis-
sue material consisted of two different histological sub-
types, intestinal (n = 9) and diffuse (n = 4) and the
tumors were located at two different sites of the sto-
mach, the corpus (n = 8) and the antrum (n = 5). Alto-
gether 111 gastric tissues and 7 gastric cancer cell lines
were included in the qRT-PCR and the affinity capture
based transcript assay (TRAC) analyses (Additional file
1: Clinical parameters). The tissue samples consisted of
43 nonmalignant and 68 cancerous gastric tissues and
both histological subtypes of gastric cancer were repre-
sented (intestinal, n = 42; diffuse, n = 25; one of
unknown histology). Gastric tissue samples were stored
Table 1 Clinical parameters for the samples analyzed on array comparative genomic hybridization (aCGH) and
expression microarrays.
Primary gastric tumors Age/sex Histology Location
14TA 58/M Intestinal Corpus
200A 57/F Intestinal Corpus
222A 50/M Intestinal Corpus
232A 83/M Intestinal Corpus
3TC 57/F Intestinal Corpus
4T/N 72/M Intestinal Corpus
10TB 59/M Intestinal Antrum
17TA 77/M Intestinal Antrum
185B 78/F Intestinal Antrum
1AT/N 41/F Diffuse Corpus
6TB 77/F Diffuse Corpus
9TD 74/F Diffuse Antrum
13TA 56/F Diffuse Antrum
Gastric cancer cell lines Age/sex Histology Origin
AGS 54/F Adeno-carcinoma Primary tumor
KATOIII 55/M Diffuse Pleural effusion
MKN-1 72/M Adeno-squamous carcinoma Lymph node metastasis
MKN-7 39/M Intestinal Lymph node metastasis
MKN-28 70/F Intestinal Lymph node metastasis
MKN-45 62/F Diffuse Liver metastasis
TMK-1 21/M Diffuse Lymph node metastasis
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at -80°C. To verify the tumor percentage and histology
of the samples, frozen samples were embedded in Tis-
sue-Tek OCT Compound (Sakura Finetek, Torrance,
CA, USA) and 5 μm frozen ice-sections were prepared
and stained using Trypan Blue. Histology of gastric can-
cer specimens was evaluated by an experienced patholo-
gist (M.-L. K.-L.). Tissue-Tek was removed from the
tissues prior to nucleic acid extractions.
AGS and KATOIII cell lines were obtained from
American Type Culture Collection (Rockville, MD,
USA) and MKN-1, MKN-7, MKN-28, MKN-45, and
TMK-1 cell lines were a kind gift from Hiroshi Yoko-
zaki, Kobe University Graduate School of Medicine,
Kobe, Japan [26]. AGS cells were grown in Kaighn’s F12
medium (2 mM glutamine, 10% FBS, 100 U/ml penicil-
lin-streptomycin), KATOIII cells in IMDM medium (2
mM glutamine, 10% FBS, 100 U/ml penicillin-strepto-
mycin) and all other cell lines in RPMI-1640 medium
(10% FCS, 2 mM glutamine, 100 U/ml penicillin-strep-
tomycin). All cells were grown at 37°C and 5% CO2.
RNA and DNA extraction
Prior to RNA and DNA extractions, the frozen tissue
was immersed in RNAlater-ICE reagent (Ambion, Aus-
tin, TX, USA) and stored at -80°C for 16 hours to stabi-
lize the RNA. Half of the tissue sample (~ 25 mg) was
homogenized in RLT-b-mercaptoethanol lysis buffer
(RNeasy mini kit, Qiagen Inc., Hilden, Germany) and
the other half in ATL-buffer (DNeasy Blood and Tissue
Kit, Qiagen) using the Ultra-Turrax homogenizer (IKA
Works, Wilmington, NC, USA). RNA was extracted
using the RNeasy mini kit, including the optional DNase
treatment, and DNA using the DNeasy Blood and Tis-
sue Kit. For gastric cancer cell lines, 1 × 107 cells were
lysed using a syringe and needle in either RLT-b-mer-
captoethanol lysis buffer or ATL-buffer prior to RNA
and DNA extractions, respectively. RNA and DNA con-
centrations were measured using NanoDrop1000
(Thermo Fisher Scientific, Waltham, MA, USA) and
RNA quality was evaluated using Agilent’s 2100 Bioana-
lyzer (Agilent Technologies, Palo Alto, CA, USA). Only
RNAs showing distinct 18S and 28S ribosomal peaks in
the Bioanalyzer analysis and 260/280 ratios above 2.0
were accepted for further analysis.
Array CGH and gene expression microarray analyses
Thirteen gastric tumors and seven gastric cancer cell
lines were analyzed on the 244K Human Genome CGH
oligoarrays (G4411B, Agilent Technologies). Three of the
tumors and all of the seven cell lines were also analyzed
using the 44K Whole Human Genome gene expression
oligoarrays (G4112F, Agilent Technologies) (Figure 1).
The mean 260/280 ratios for these samples were 2.1 for
RNA and 1.8 for DNA, and all of the RNA samples had
clear 18S and 28S ribosomal peaks in the Bioanalyzer
analysis indicating good quality (data not shown). Array
CGH experiments were performed using Human Gen-
ome CGH Microarray 244A kit (Agilent Technologies).
Labeling and hybridization were performed according to
the Agilent’s protocol (v5.0, June 2007). In brief, 1.5 μg of
sample DNA and 1.5 μg of sex-matched reference DNA
(Human Genomic DNA, Promega, Madison, WI, USA)
were double-digested with AluI and RsaI restriction
enzymes (Promega). The digested DNA was labeled
using the Agilent Genomic DNA Labeling Kit Plus. Sam-
ple DNA was labeled with Cy5-dUTP and reference
DNA with Cy3-dUTP, respectively. Labeled DNA was
purified with Microcon YM-30 filters (Millipore, Billerica,
MA, USA). Following the purification, sample and refer-
ence DNAs were pooled and hybridized to the array with
50 μg of Human Cot-1 DNA (Invitrogen, Carlsbad, CA,
USA) at 65°C, 20 rpm for 40 h. Hybridization was per-
formed with Agilent Oligo aCGH Hybridization Kit.
Prior to scanning, the slides were washed according to
the protocol. In addition to the sample DNA hybridiza-
tions described above, reference male DNA (Cy3) was
hybridized against reference female DNA (Cy5) accord-
ing to the same protocol to be used as a reference array
in the aCGH data analysis.
Gene expression experiments were performed using
the Whole Human Genome Oligo Microarray kit (Agi-
lent Technologies), and labeling and hybridization
according to the Agilent protocol (v5.7, March 2008). In
brief, 2 μg of total sample RNA and reference RNA (a
pool of 10 cancer cell lines, non-gastric, ATCC, Mana-
ssas, MA, USA) were labeled using the Agilent Quick
Amp Labeling Kit. Sample RNA was labeled with Cy5-
dCTP and reference DNA with Cy3-dCTP, respectively.
Labeled RNA was then purified using RNeasy mini spin
columns (Qiagen). Hybridization was performed with
Agilent Gene Expression Hybridization Kit and samples
were hybridized at 65°C, 10 rpm for 17 h and washed
according to the protocol prior to scanning. Both aCGH
and gene expression microarray slides were scanned
using the DNA Microarray Scanner (Agilent Technolo-
gies) and analyzed with Feature Extraction Software
(v9.5.1.1.).
High-resolution copy number profiling
All copy number data is available at http://www.cangem.
org (accession number: CG-EXP-49) [27]. Agilent’s CGH
Analytics software (v3.5.14) was applied to identify the
copy number changes. Microarray data was quality filtered
using the outlier information obtained from the Feature
Extraction analysis. Probes flagged as outliers were
removed from further analysis. In addition, the following
aberration filters were applied: minimum number of
probes in region = 3, minimum absolute log2 ratio for
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region = 0.27, and maximum number of aberrant regions
= 1000. The log2 ratio of 0.27 corresponds to a 1.2-fold
change in the copy number. In CGH Analytics, each
aCGH ratio was first converted to a log2 ratio followed by
a Z-normalization. The male vs. female reference array
was used as a calibration array in the data analysis.
Because of the gender differences between the arrays that
could cause bias in the analysis, chromosomes X and Y
were excluded from the calibration. ADM-2 algorithm
with a threshold level of 12.0 was used to identify gene
copy number alterations in individual samples and cell
lines. Minimal common regions of alterations in the 20
samples were calculated, including the size and chromoso-
mal position of the alteration in base pairs. An aberration
was defined as recurrent, if it was present in at least 25%
of the samples (Table 2).
Gene expression microarray analysis
All gene expression data is available at http://www.can-
gem.org (accession number: CG-EXP-49) [27]. Microarray
results were quality filtered using outliers defined by the
Feature Extraction Software and normalized according to
the Loess method, which was included in the software
package. The gene expression analysis was restricted to
genes located in the chromosomal regions with recurrent
aberrations (Table 2). The goal of this approach was to
highlight gene expression changes that were associated
with changes in the gene copy number, and could there-
fore represent potential oncogenes or tumor suppressor
genes with a functional role in cancer. First, a median
log10 expression ratio was calculated for all the probes tar-
geting the same gene. Then, in two separate analyses for
gains and losses, the median expression level of each gene
was compared between the samples with copy number
gain/loss and samples with normal copy number to evalu-
ate the effect of copy number alterations on gene expres-
sion. Gene expression fold changes (FC) were calculated
either by dividing the median expression of the cancerous
samples by the median expression of the nonmalignant
samples or by dividing the median expression of cancer
Figure 1 Flowchart describing different steps of the study.
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samples with copy number alterations (g1) by the median
expression of cancer samples with normal copy number
(g0). At least a 2-fold copy number associated change in
gene expression was considered significant. Based on this
data, 13 genes ALPK2, ASAP1, CEACAM5, CYP3A4,
ENAH, ERBB2, HHIPL2, LTB4R, MMP9, OSMR, PERLD1,
PNMT, and PTPRA, were chosen to be further validated
with qRT-PCR analysis and TRAC (transcript analysis
with aid of affinity capture) assay. The results from the
integrated microarray analysis were compared with three
previously published studies that systematically integrate
genome-wide copy number and gene expression data
[15-17].
Real-time qRT-PCR analysis
Real-time qRT-PCR was performed for 2 genes, ALPK2
(18q21.31-q21.32) and HHIPL2 (1q41). The expression
levels were measured in 82 gastric tissues (46 cancerous
and 36 nonmalignant tissues) and in 7 gastric cancer
cell lines (Additional file 1: Clinical parameters). 1 μg of
total RNA was converted to cDNA using Moloney-mur-
ine leukemia virus reverse transcriptase (Promega, Madi-
son, WI, USA) and random primers (Invitrogen) in a
volume of 50 μl for 1 h at 37°C. The reaction was heat-
inactivated (95°C, 3 min) and filled to a final volume of
200 μl with molecular grade water. The transcripts were
quantitated using the Assays-on-DemandTM gene
expression products (Hs01085414_m1 for ALPK2 and
Hs00226924_m1 for HHIPL2) according to the manu-
facturer’s protocol (Applied Biosystems, Foster City, CA,
USA). All primers were located on exon-exon
boundaries. Briefly, 2 μl of cDNA template was mixed
with 1.25 μl of specific primers and probes labeled with
FAM-reporter dye. 12.5 μl of TaqMan® Universal PCR
Mastermix and RNase-free water were added to a total
volume of 25 μl. Human 18S rRNA served as an endo-
genous control to normalize the expression levels in the
subsequent quantitative analysis. The 18S probe was
labeled with VIC-reporter dye to allow multiplex PCR
with the target genes. The PCR conditions were as
follows: 50°C for 2 min, 95°C for 10 min, followed by 40
cycles of 95°C for 15 s and 60°C for 1 min. Each sample
was measured in triplicate and the data were analyzed
by the delta-delta method for comparing relative expres-
sion results (2-[Ct sample-Ct control]).
TRAC assay
Transcript analysis with aid of affinity capture (TRAC)
assay [28] was performed for 11 different genes in 88
gastric tissues (53 cancerous and 35 nonmalignant tis-
sues) and 7 gastric cancer cell lines (Additional file 1:
Clinical parameters). The genes included in the analysis
were ENAH (1q42.12), OSMR (5p13.1), CYP3A4
(7q21.1) ASAP1 (8q24.1-q24.2), LTB4R (14q11.2-q12),
PERLD1 (17q12), ERBB2 (17q21.1), PNMT (17q21-q22),
CEACAM5 (19q13.1-q13.2), PTPRA (20p13), and MMP9
(20q11.2-q13.1). The advantage of the TRAC assay is
that the expression levels of multiple genes can be mea-
sured simultaneously from a single sample thus lowering
the amount of sample RNA required for the analysis.
This is especially important for the analysis of often
scarce clinical tissue samples.
Table 2 Minimal common regions of recurrent (≥25%) copy number alterations.
Alteration Tissues
(n = 13)
Cell lines
(n = 7)
Frequency Size
(Mb)
Position (Mb) Possible target genes
+1q41-q43.1 2 3 25% 17.30 216.31-233.61 ENAH, AGT, CAPN2, LEFTY2, LGALS8
+5p13.3-q11.1 1 4 25% 19.41 30.18-49.60 OSMR, RNASEN
+7q21.3-q22.1 4 3 35% 4.60 97.33-101.93 CYP3A4, AZGP1, VGF
+8q24.13-q24.3 3 2 25% 19.8 126.45-146.25 ASAP1, BAI1, KHDRBS3
+8q24.3 6 3 45% 2.23 143.59-145.82 GML, LYPD, AK3
+14q11.2 0 5 25% 1.05 22.89-23.94 LTB4R
+17q12-q21.1 3 3 30% 0.28 35.02-35.30 ERBB2, PPP1R1B, PERLD1, PNMT
+17q22-q24.2 2 3 25% 13.65 50.45-64.10 AXIN2, RNF43
+19q12-qter 4 3 35% 29.36 33.89-63.25 CEACAM5, APOC1, APOE, CEACAM7, FTL, FUT1, GPR4, HPN,
KCNN4, KLK1, KLK12, LYPD3, NLRP7, CCNE1
+20p13-qter 5 3 40% 57.94 0.04-57.98 PTPRA, BLCAP, CD40, CHGB, CST3, EYA2, PI3, ID1, MMP9, BMP7
-9p24.3-p21.1 3 4 35% 27.81 1.05-28.86 MTAP, CD274, INSL4, JAK2, MLANA, SMARC2, TUSC1
-18q12.3-q22.2 3 5 40% 26.11 39.48-65.59 SMAD7, SERPINB2/B3/B4/B5
-18q22.3-qter 2 5 35% 3.69 70.95-74.65 TSHZ1
-21q11.2-q21.1 3 3 30% 4.07 14.37-19.44 HSPA13
-Xq28 4 1 25% 1.21 152.24-153.45 -
Number of cases, size of the minimal common regions (Mb), and the chromosomal position of the alteration (Mb) are indicated as well as possible target genes.
CNV regions are not shown in the table. Copy number gain (+), copy number loss (-).
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TRAC analysis was performed at PlexPress (Helsinki,
Finland). Custom TRACPackTM reagents for mRNA
(PlexPress) were used in the analysis. Briefly, 90 μl of
Hybridization Mix (containing labeled gene-specific
detection probes and biotinylated oligo-dT probes) per
well was dispensed to a 96-well PCR plate. Two micro-
grams of RNA sample was applied to each well in a 100
μl total reaction volume. An equal amount (30 amol/
reaction) of single stranded 62-mer synthetic oligonu-
cleotide hybridization control, including a poly-A tail,
was added to each sample prior to hybridization. Hybri-
dization was performed at 60°C, 650 rpm for 120 min-
utes (Thermomixer Comfort, Eppendorf, Hamburg,
Germany). After hybridization affinity capture, purifica-
tion, and elution were done using the KingFisher Flex
(Thermo Fisher Scientific, Vantaa, Finland) magnetic
particle processor. Streptavidin-coupled magnetic
TRACPACK™ beads (50 μg, PlexPress) were added to
the hybridization mixture and allowed to bind to the
biotinylated mRNA-probe-oligo(dT)-hybrids for 30 min-
utes, after which the beads were washed 5 times using
wash buffer to remove any unbound material. Labeled
RNA-specific probes were eluted with elution buffer and
detected by capillary electrophoresis, using the ABI3100
sequencer (Applied Biosystems, Cheshire, UK). The data
was analyzed using the TRACParser software
(PlexPress).
Statistical analysis of the qRT-PCR data
A nonparametric Mann-Whitney test for two indepen-
dent samples was applied to determine the statistical
significance of differences in the relative mRNA expres-
sion levels of ALPK2 and HHIPL2 in nonmalignant
and cancerous gastric samples as well as in gastric
cancer samples of different histological subtypes or
TNM-stages. A p-value < 0.05 was considered statisti-
cally significant (SPSS 17.0). In addition, in two separate
analyses for gains and losses, the expression levels in
cancer samples with copy number gains or losses (g1)
were compared to cancer samples with normal copy
number (g0) to assess the association between copy
number and gene expression. Copy number data were
available for 37 of the gastric samples included
in the qRT-PCR analysis (Additional file 1: Clinical
parameters). Gene expression fold changes were
calculated by dividing the mean expression of one group
(e.g. cancer samples) by the mean expression of the
other group (e.g. nonmalignant samples).
Statistical analysis of the TRAC assay data
A synthetic hybridization control was used in the data
normalization to remove any non-biological variation in
the data. For each target, signal intensities relative to
this internal hybridization control were calculated. For
the nine tissue samples analyzed in replicate mean signal
intensity was used. A nonparametric Mann-Whitney test
for two independent samples was applied to determine
the statistical significance of differences in the relative
mRNA expression levels of ASAP1, CEACAM5,
CYP3A4, ENAH, ERBB2, LTB4R, MMP9, OSMR,
PERLD1, PNMT, and PTPRA in nonmalignant and can-
cerous gastric samples as well as in gastric cancer sam-
ples of different histological subtypes or TNM-stages.
A p-value < 0.05 was considered statistically significant
(SPSS 17.0). The comparison of gene expression levels
in samples with and without copy number alterations
was performed as was described before for the qRT-
PCR analysis. Copy number data were available for 43
gastric cancer samples included in the TRAC assay
analysis.
Results
Gene copy number aberrations
All gene copy number changes in individual samples are
shown in the Additional file 2: Copy number changes
detected by aCGH analysis. Minimal common regions of
recurrent (≥25%) alterations as well as their size, fre-
quency, possible target genes, and chromosomal position
in base pairs are shown in Table 2. The recurrent gained
regions were located at 1q41-q43.1 (25%), 5p13.3-q11.1
(25%), 7q21.3-q22.1 (35%), 8q24.13-q24.3 (25%), 8q24.3
(45%), 14q11.2 (25%), 17q12-q21.1 (30%), 17q22-q24.2
(25%), 19q12-qter (35%), and 20p13-qter (40%). The
recurrent deleted regions were located at 9p24.3-p21.1
(25%), 18q12.3-q22.2 (40%), 18q22.3-qter (35%),
21q11.2-q21.1 (30%), and Xq28 (25%). All recurrent
copy number changes were detectable both in primary
gastric cancers and in gastric cancer cell lines, except
for the 14q11.2, which was altered only in five cell lines.
Copy number associated gene expression changes
Altogether 256 individual genes (10% of all genes
located in the recurrent chromosomal regions with copy
number alterations) showed at least a 2-fold copy num-
ber associated change in their expression (range 2.0 -
34.6, median 3.8) (Additional file 3: Copy number asso-
ciated gene expression changes). 226 of these genes
were overexpressed and located in recurrent regions of
copy number gains, whereas 30 genes were underex-
pressed and located in recurrent regions of copy num-
ber losses. Fold change in gene expression was
calculated by comparing the expression levels of sam-
ples with copy number alterations to samples with nor-
mal copy number in a given gene. Therefore, a positive
fold change refers to a copy number gain related
increase in gene expression whereas a negative fold
change refers to a copy number loss related decrease in
gene expression.
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HHIPL2 (HHIP-like 2) gene, amplified in the 1q41-
q43.1 region, showed the highest copy number gain
associated overexpression in gastric cancer according to
the integrated microarray analysis (FC = 26.9). Gener-
ally, the highest gene expression fold changes between
cancer samples with and without copy number gains
were detected at the 19q region since out of the 40
genes showing >5-fold copy number associated changes
in their expression, 19 (47.5%) were located in the 19q
region (Additional file 3: Copy number associated gene
expression changes). The most underexpressed gene in
the recurrent regions of copy number losses was ALPK2
(alpha-kinase 2) (FC = -34.6) located at 18q12.3-q22.2.
Previously, three studies by us and others have been
published that systematically integrate genome-wide copy
number and gene expression data to identify genes whose
expression has changed due to a copy number alteration
in gastric cancer [15-17]. The comparison of the overlap-
ping genes between these studies and the current study
revealed 20 genes TOMM20 (1q42.3), GGPS1 (1q43),
CYP3A4 (7q21.1), MTAP (9q21.3), ASAP1 (8q24.1-q24.2),
PPP1R1B (17q12), ERBB2 (17q12-q21), SERPINB3
(18q21.3), SERPINB8 (18q21.3),WDR7 (18q21.2-q22),
HIF3A (19q13.32), ZNF480 (19q13.33), IL4I1 (19q13.3-
q13.4), CST3 (20p11.21), PTPRA (20p13), SLC13A3
(20q12-q13.1), DDX27 (20q13.13), PARD6B (20q13.13),
SGK2 (20q13.2), and TUBB1 (20q13.32) that were either
gained and overexpressed or deleted and underexpressed
in our study and in at least one of the previously published
studies. Previously published data together with the cur-
rent results provide further evidence of the biological role
of these genes in gastric cancer.
Validation of potential gastric cancer target genes
Real-time qRT-PCR analysis showed that the expression
of HHIPL2 was 7.4-fold higher in gastric cancer samples
compared with the nonmalignant gastric tissues (p <
0.05). In addition, the overexpression of HHILP2 was
significantly associated with copy number gain (p <
0.05) as the expression of HHIPL2 was 17.4-fold higher
in cancer samples with copy number gain of HHIPL2
(g1) than in cancer samples with normal copy number
of this gene (g0) (Tables 3 and 4). According to the
qRT-PCR analysis there was a 2.9-fold underexpression
of ALPK2 in gastric cancers with copy number losses
(g1) compared with gastric cancers with normal copy
number of ALPK2 (g0) (p < 0.05). Surprisingly, however,
the expression of ALPK2 in gastric cancers in general
was 1.9-fold higher (p < 0.05) than in the nonmalignant
gastric tissues (Tables 3 and 4). Histological subtype or
TNM-stage did not have a statistically significant effect
on the expression of HHIPL2 or ALPK2 (Table 3).
Multiplex gene expression analysis of 11 additional
genes showing copy number gain associated overexpres-
sion according to the microarray analysis was carried
out using the TRAC assay. All of these genes showed
statistically significant differences in their mRNA
expression in nonmalignant vs. cancerous gastric tissues.
The p-values for each individual gene are shown in
Table 3. The copy number gain related overexpression
was detected for seven of these genes, including
CYP3A4, ENAH, ERBB2, MMP9, PERLD1, PTPRA, and
OSMR (p < 0.05, Table 3), which thereby validates the
results from the integrated microarray analysis. Histolo-
gical subtype or TNM-stage did not have a statistically
significant effect on the expression of the tested genes
(Table 3).
Discussion
Gene copy number alteration is known to be an impor-
tant mechanism for a cancer cell to regulate the expres-
sion of cellular proto-oncogenes and tumor suppressor
Table 3 Results of the nonparametric Mann-Whitney test for the qRT-PCR and TRAC analysis data (SPSS17.0).
Gene Chromosome Cancer vs. non-malignant intestinal vs. diffuse g1 vs. g0 M0 vs. M1 T1-2 vs. T3-4 N0 vs. N1-3
ALPK2 18q21.31-q21.32 p < 0.05 p = 0.104 p < 0.05 p = 0.451 p = 0.072 p = 0.378
ASAP1 8q24.1-q24.2 p < 0.001 p = 0.319 p = 0.396 p = 0.208 p = 0.232 p = 0.289
CEACAM5 19q13.1-q13.2 p < 0.001 p = 0.061 p = 0.254 p = 0.543 p = 0.197 p = 0.253
CYP3A4 7q21.1 p < 0.001 p = 0.061 p < 0.05 p = 0.355 p = 0.228 p = 0.422
ERBB2 17q21.1 p < 0.001 p = 0.168 p < 0.05 p = 0.490 p = 0.350 p = 0.314
HHIPL2 1q41 p < 0.05 p = 0.248 p < 0.05 p = 0.847 p = 0.129 p = 0.736
PNMT 17q21-q22 p < 0.001 p = 0.649 p = 0.346 p = 0.133 p = 0.824 p = 0.136
PERLD1 17q12 p < 0.001 p = 0.316 p < 0.05 p = 0.437 p = 0.208 p = 0.161
PTPRA 20p13 p < 0.001 p = 0.304 p < 0.05 p = 0.112 p = 0.953 p = 0.596
ENAH 1q42.12 p < 0.001 p = 0.290 p < 0.05 p = 0.149 p = 0.949 p = 0.342
LTB4R 14q11.2-q12 p < 0.001 p = 0.427 p = 0.422 p = 0.468 p = 0.452 p = 0.604
MMP9 20q11.2-q13.1 p < 0.001 p = 0.495 p < 0.05 p = 0.089 p = 0.496 p = 0.238
OSMR 5p13.1 p < 0.001 p = 0.548 p < 0.05 p = 0.182 p = 1.000 p = 0.184
g1, gastric cancer samples with copy number gain/loss; g0, gastric cancer samples with normal copy number.
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genes. Recent studies by us and others have demon-
strated that 10-15% of all gene expression changes are
directly associated with gene copy number changes and
10-45% of the amplified genes are overexpressed in dif-
ferent epithelial tumors and cell lines [16,17,21,22]. In
the present study, our aim was to screen for those genes
that are differentially expressed in association with copy
number alteration and to identify potential molecular
markers with a biological role in gastric carcinogenesis.
Our approach was to screen for DNA copy number
changes using a high-resolution array-based analysis
combined with measurement of transcriptional activities
of the genes located in the recurrent regions of copy
number alterations using both gene expression arrays as
well as qRT-PCR and TRAC analyses. On the whole, we
identified recurrent copy number gains in 10 chromoso-
mal regions and losses in 5 regions, which are in con-
cordance with the previous studies [8-17,29]. The
majority of the identified gains and losses were observed
in multiple tumors and cell lines suggesting genomic
alterations with an important biological role in gastric
cancer.
Altogether, 10% of all the genes located in the recur-
rent regions of copy number alterations were over- or
underexpressed along with the copy number change.
This is in line with previous reports on the impact of
copy number on gene expression in solid tumors
[17,18,20-22]. A literature search showed that 50 of
these genes (37 up- and 13 down-regulated genes) had
previously been reported to have mutations, polymorph-
isms, copy number and/or expression changes in malig-
nant tumors, and 4 of the genes (ERBB2, JAK2, LIFR,
and ZNF331) are included in the Cancer Gene Census
of the Wellcome Trust Sanger Institute [30]. Further-
more, 14 of the identified genes (AGT, APOC1, APOE,
AXIN2, CEACAM5, ERBB2, HSPA13, ID1, KLK12,
MMP9, PPP1R1B, PTPRA, SERPINB5, and SMAD7)
have previously been associated with malignant gastric
tumors.
In the current study, the association between copy
number and gene expression varied among different
genes. ALPK2 showed the strongest association between
copy number loss and underexpression according to the
integrated microarray analysis. The frequency of copy
number loss of ALPK2 in our data was 40%. The copy
number associated underexpression in gastric cancers
was validated with qRT-PCR analysis as ALPK2 showed
a 2.9-fold underexpression in gastric cancers with copy
number losses (g1) compared with gastric cancers with
normal copy number of ALPK2 (g0). However, the
underexpression of ALPK2 in gastric cancers in general
compared to normal gastric tissues was not detected.
ALPK2 is located in the 18q12.3-q22.2 region, a region
of recurrent genomic loss in gastric cancers. No pre-
vious publications regarding the possible tumor associa-
tion of ALPK2 or its function in normal tissues have
been published. The 18q region is also known to harbor
two well-known gastric cancer associated tumor sup-
pressor genes DCC (18q21.3) and SMAD4 (18q21.1)
[15,31,32]. However, these genes did not show a correla-
tion between copy number and gene expression in our
data.
The HHIPL2 gene showed the highest copy number
gain associated overexpression according to the inte-
grated microarray analysis. The frequency of copy num-
ber gain of HHIPL2 in our data was 25%. The
overexpression was validated with the qRT-PCR analysis
as HHIPL2 showed a 7.4-fold overexpression in gastric
cancers compared to the normal tissues. Furthermore,
the expression was 17.4-fold higher in gastric cancers
with copy number gains compared to the gastric cancers
with normal copy number of this gene. This is the first
Table 4 Genes showing an association between copy number and expression in gastric cancer.
Gene Chromosome Fold change cancer
vs. normal
p-value cancer
vs. normal
Fold change
g1 vs. g0
p-value g1
vs. g0
Previous reports in
gastric cancer
PubMed IDs
ALPK2 18q21.31-q21.32 1.9 p < 0.05 -2.9 p < 0.05 - -
CYP3A4 7q21.1 8.9 p < 0.001 2.4 p < 0.05 polymorphisms 17605821
ENAH 1q42.12 8.4 p < 0.001 3.8 p < 0.05 - -
ERBB2 17q21.1 3.5 p < 0.001 1.8 p < 0.05 amplification and
overexpression
14991576,
19156142, 17555797
HHIPL2 1q41 7.4 p < 0.05 17.4 p < 0.05 -
MMP9 20q11.2-q13.1 4.8 p < 0.001 1.7 p < 0.05 overexpression,
polymorphisms
18437914,
18451255, 16237750
OSMR 5p13.1 3.4 p < 0.001 2.4 p < 0.05 - -
PERLD1 17q12 3.4 p < 0.001 3.0 p < 0.05 amplification and
overexpression
16849520
PTPRA 20p13 4.1 p < 0.001 1.3 p < 0.05 overexpression 16338072
Gene expression fold changes according to the qRT-PCR and TRAC analyses and p-values from nonparametrical Mann-Whitney test are shown (SPSS 17.0). g1,
gastric cancer samples with copy number gain/loss; g0, gastric cancer samples with normal copy number.
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study to report an association of HHIPL2 with gastric
cancer. HHIPL2 is a transmembrane protein containing
a short N-terminal cytoplasmic region. It belongs to the
HHIP gene family and is expressed in the testis, thyroid
gland, osteoarthritic cartilage as well as in pancreatic
and lung cancers [33]. Overexpression of HHIPL2 has
not been previously associated with any cancers and its
exact biological function is not known. However,
another member of the HHIP family, HHIP1, is known
to interact with proteins of the Hedgehog signaling
pathway [33]. This association could possibly also offer
an explanation for HHIPL2’s role in gastric cancer.
To further highlight the clinical significance of the
genes mapping to recurrent copy number altered
regions in gastric cancers as well as to validate the
microarray results, eleven genes were selected for the
affinity capture based transcript analysis (TRAC assay).
These eleven genes were selected based on their copy
number associated gene expression changes detected in
the integrated microarray analysis, as well as based on
their previously published associations with cancer. The
TRAC assay has previously been shown to correlate well
with the conventional qRT-PCR and Northern blot ana-
lyses [28,34]. The TRAC analysis validated the results
obtained from the microarray analysis since all of the
genes showing overexpression in the microarray analysis
also showed an increased expression in the TRAC analy-
sis. Seven out of these genes also showed copy number
gain associated overexpression. Overexpression in
samples with copy number alterations compared with
samples with normal copy number ranged from 1.7 to
3.8-fold (Table 4) and in gastric cancers in general
these seven genes were overexpressed 3.5 to 8.9-fold
compared with normal tissues (Table 4).
ERBB2 and PERLD1 have been previously been
reported to be gained and overexpressed in gastric can-
cers [17,23,35]. Both of these genes are part of the
PPP1R1B-STARD3-TCAP-PNMT-PERLD1-ERBB2-
MGC14832-GRB7 locus at the 17q12 region, which has
previously been reported to be gained and overexpressed
in breast and gastric cancers [23,35-38]. We have pre-
viously reported PERLD1 to have a copy number gain in
18.4% of primary gastric tumors [17]. In the current
study, PERLD1 was amplified in 30% gastric cancers and
copy number gain caused a 3.0-fold overexpression (p <
0.05) of this gene.
In addition to ERBB2 and PERLD1, the TRAC analysis
also identified five novel genes, CYP3A4, ENAH, MMP9,
PTPRA, and OSMR, which have not been reported as
gained and overexpressed in gastric cancer before. Of
these OSMR and ENAH are especially interesting since
they have no previous link to gastric carcinogenesis.
Oncostatin M (OSM) is a member of the interleukin-6
cytokine family that binds to its receptor, OSMR, to
induce signals important to hematopoiesis, inflamma-
tion, bone remodelling, heart development, and neuro-
genesis [39]. ENAH is an actin binding protein involved
in the regulation of cell motility [40]. The frequency of
copy number gain for both OSMR and ENAH in our
data was 25%. OSMR and ENAH showed overexpression
in samples with copy number gains compared to sam-
ples with normal copy number (p < 0.05, FC 2.4 for
OSMR and 3.8 for ENAH) as well as in gastric cancers
in general compared to the normal gastric tissues (p <
0.001, FC 3.4 for OSMR and 8.4 for ENAH). Ng et al.
(2007) [41] demonstrated that gene copy number and
expression levels of OSMR were increased in cervical
squamous cell carcinomas and that overexpression was
associated with poor survival of these patients. However,
to our knowledge no previous studies exist that link
OSMR expression and copy number changes to gastric
carcinogenesis. The overexpression of ENAH has pre-
viously only been reported in breast cancer [42].
The gastric cancer-related overexpression of PTPRA
and MMP9 has previously been implicated [43-45] but
the association between copy number and overexpres-
sion has not been reported. The role of PTPRA in gas-
tric cancer might be linked to its biological role in
integrin signalling, cell adhesion, and activating the SRC
family tyrosine kinases. MMP9 is known to be overex-
pressed many epithelial tumors including gastric tumors
[46-48] and its involvement in the breakdown of extra-
cellular matrix could explain its role in gastric cancer
progression and formation of metastases. The overex-
pression of CYP3A4 has been reported in breast cancer
[49] but not in gastric cancer. In all, the combined
microarray and transcript analysis highlighted several
interesting genes as potential target genes for gastric
cancer.
Conclusions
To conclude, the present results prove that integrated
analysis of gene copy number and expression levels is
an effective approach in identifying potential biomarkers
for gastric cancer. All of the genes, identified based on
their association of copy number and gene expression in
the microarray analysis, were also differentially
expressed in cancerous gastric samples compared to
nonmalignant tissues according to the qRT-PCR and
TRAC analyses. Copy number-associated gene expres-
sion changes were confirmed for 9 out of the 13 (69.2%)
genes (ALPK2, CYP3A4, ENAH, ERBB2, HHIPL2,
MMP9, PERLD1, PTPRA, and OSMR) thereby validating
the results from the integrated microarray analysis and
highlighting these genes as potential biomarkers for
gastric cancer. Further studies are however required to
decipher their biological significance in gastric cancer
initiation and progression.
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